Login to Your Account


'We'll be giving a lot less chemotherapy'

For the treatment of breast cancer, the biggest newsmaker at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago had nothing to do with drug development. 

more »


Our Habitat for All Things Science
Ibrutinib could be repurposed to treat glioblastoma

HONG KONG – Preclinical data from a Sino-US study suggest that a tyrosine kinase inhibitor originally developed to treat lymphoma and leukemia, Imbruvica (ibrutinib, Abbvie Inc./Johnson & Johnson), could also target glioma stem cells (GSCs), effectively controlling glioblastoma growth.

Despite therapeutic advances in other solid tumors, glioblastoma remains the most lethal primary brain tumor. It is highly resistant to current treatments including radiotherapy and chemotherapy. The cancer usually recurs rapidly, with a median survival of less than 15 months from diagnosis.

READ MORE »

Opinion


Partners in Focus